A blog from Grace weighs the evidence behind peptide therapy, covering both possible benefits and the risks. Thin on specifics in the shared post.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Buchanan Ingersoll & Rooney outlines what compounding pharmacies should watch for now that the FDA has sent its interim peptide policy to the White House for review.
Investseekers cites IQVIA data showing Lilly still leading the US obesity market while Novo's Wegovy line declined.
Loading…